Skip Over Navigation Links

Small Molecule Treatment for Rheumatoid Arthritis

Kemmx Corporation, Sapulpa, OK is developing 6-diazo-5-oxo-L-norleucine (DON) as a topical analgesic for rheumatoid arthritis sufferers. We have discovered that DON can block glutamate production in arthritic sensory nerves of the skin and local produce pain relief that lasts for 24 hours or more.

Kemmx will continue research and development on topical formulation, drug stability and the analgesic dose response for DON. The outcome of the above objectives at the NCI and development at Kemmx will allow the company to pursue pharmacokinetic and toxicology studies, an Investigative New Drug (IND) filing, and phase I clinical trials for DON. It is the goal of Kemmx Corporation to receive FDA approval and enter into clinical trials with a highly innovative topical analgesic for rheumatoid arthritis sufferers.

Key Investigator

Kemmx Corporation
Kenneth Miller, Ph.D.

Public Health Impact

Kemmx Corporation, Sapulpa, OK is developing 6-diazo-5-oxo-L-norleucine as a topically applied pain reliever for rheumatoid arthritis sufferers. Partnership of Kemmx Corporation and the NIH will help bring forward 6-diazo-5-oxo-L-norleucine for Food and Drug Administration approval.

Outcomes

Approved studies are ongoing.

Project Details

  • Synthesis of GMP and non-GMP material
  • IND-directed toxicology

Contact

Tony Jackson